The SPEARHEAD-1 phase 2 trial [81] demonstrated efficacy in heavily pretreated, advanced SS (43% objective response rate; median duration of response 6 months), leading to FDA approval for unresectable or metastatic SS expressing MAGE-A4 in an appropriate HLA context. Here, MAGEA4 is linked to synovial sarcoma.